Cardio-oncology
Consensus Statement | Cardiac computed tomographic imaging in cardio-oncology.
22 Sep, 2022 | 13:07h | UTC
Commentary on Twitter
New SCCT Expert Consensus co-endorsed by @ICOSociety: #YesCCT in Cardio-Oncology
This document fills existing gaps about CCT in Cardio-Oncology w experts in cardio-oncology, CCT imaging and cancer medicine @journalCCT 👉https://t.co/lNaQ37sKoQ@onco_cardiology @CardiacCTGuy pic.twitter.com/hILbBimfmZ
— Heart_SCCT (@Heart_SCCT) September 19, 2022
Large study unravels the risk factors for heart failure among childhood cancer survivors.
11 Sep, 2022 | 22:22h | UTC
Review | Cardiovascular complications of immune checkpoint inhibitors for cancer.
6 Sep, 2022 | 14:20h | UTCCardiovascular complications of immune checkpoint inhibitors for cancer – European Heart Journal
Related:
Cardiotoxicity of immune checkpoint inhibitors – ESMO Open
Cardiotoxicity from immune checkpoint inhibitors – IJC Heart & Vasculature
Commentary on Twitter
Must read state-of-the-art review: Cardiovascular complications of immune checkpoint inhibitors for cancer https://t.co/0lr7g6s8g0
#EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes pic.twitter.com/jORaTzP7GD— European Society of Cardiology Journals (@ESC_Journals) September 5, 2022
#ESCCongress | 2022 ESC Guidelines on cardio-oncology.
29 Aug, 2022 | 12:17h | UTCNews Release: Advice to prevent heart problems caused by cancer therapy published today – European Society of Cardiology
Related guidelines:
Brazilian Cardio-oncology Guideline – 2020 – Arquivos Brasileiros de Cardiologia
Cohort Study | Association of gonadotropin-releasing hormone agonists for prostate cancer with cardiovascular disease risk and hypertension in men with diabetes.
11 Aug, 2022 | 11:54h | UTC
Commentary on Twitter
Study showed men with #T2DM on GnRH for prostate cancer had a 53% higher risk of an increase in CVD risk score than those not on GnRH, suggesting the need to control cardiovascular disease risk factors in men with T2DM receiving GnRH. #OrigInvestigation https://t.co/3cJ10PpQGN
— JAMA Network Open (@JAMANetworkOpen) August 8, 2022
Cohort Study | Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients.
28 Jul, 2022 | 13:13h | UTCNews Release: Hormone therapy for prostate cancer increases the risk of dying from cardiovascular disease – Taylor & Francis
Cohort Study | Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors.
27 Jul, 2022 | 11:53h | UTCLong-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors – Cancer
Commentaries:
CVD Mortality Leading Cause of Death for Stage I, II Hodgkin Lymphoma – HealthDay
Retrospective Cohort Study | Major adverse cardiovascular events in patients with renal cell carcinoma treated with targeted therapies.
21 Jul, 2022 | 12:54h | UTC
Review | Cardiometabolic comorbidities in cancer survivors.
19 Jul, 2022 | 13:17h | UTCCardiometabolic Comorbidities in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review
Review | Cardiovascular disease in myeloproliferative neoplasms.
14 Jul, 2022 | 12:38h | UTC
How to treat renal cell carcinoma: the current treatment landscape and cardiovascular toxicities.
14 Jul, 2022 | 12:35h | UTC
Prevalence of cardiovascular disease in patients with potentially curable malignancies: a national registry dataset analysis.
14 Jul, 2022 | 12:33h | UTC
Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy.
8 Jul, 2022 | 11:53h | UTCRelated:
AHA Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis.
M-A | Risk factors for anthracycline-induced cardiotoxicity in breast cancer treatment.
7 Jul, 2022 | 12:17h | UTC